Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors ; volume:13 ; number:2 ; day:27 ; month:1 ; year:2022 ; pages:241-250 ; date:2.2022
Diabetes therapy ; 13, Heft 2 (27.1.2022), 241-250, 2.2022
- Urheber
-
Heath, Rebecca
Johnsen, Håkon
Strain, W. David
Evans, Marc
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-022-01204-4
- URN
-
urn:nbn:de:101:1-2022052619484354700109
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Heath, Rebecca
- Johnsen, Håkon
- Strain, W. David
- Evans, Marc
- SpringerLink (Online service)
Ähnliche Objekte (12)
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
SGLT2 inhibitors in heart failure with reduced ejection fraction
Biomarkers in heart failure with preserved ejection fraction
Comorbidities in heart failure with preserved ejection fraction
Animal models of heart failure with preserved ejection fraction
Heart Failure with Preserved Ejection Fraction—a Concise Review
133 Obesity is associated with decreased myocardial contraction fraction despite preserved ejection fraction
Gender-related differences in heart failure with preserved ejection fraction
Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
Endostatin a Potential Biomarker for Heart Failure with Preserved Ejection Fraction
Evaluation of mouse models of heart failure with preserved ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
SGLT2 inhibitors in heart failure with reduced ejection fraction
Biomarkers in heart failure with preserved ejection fraction
Comorbidities in heart failure with preserved ejection fraction
Animal models of heart failure with preserved ejection fraction
Heart Failure with Preserved Ejection Fraction—a Concise Review
133 Obesity is associated with decreased myocardial contraction fraction despite preserved ejection fraction
Gender-related differences in heart failure with preserved ejection fraction
Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
Endostatin a Potential Biomarker for Heart Failure with Preserved Ejection Fraction
Evaluation of mouse models of heart failure with preserved ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
SGLT2 inhibitors in heart failure with reduced ejection fraction
Biomarkers in heart failure with preserved ejection fraction
Comorbidities in heart failure with preserved ejection fraction
Animal models of heart failure with preserved ejection fraction
Heart Failure with Preserved Ejection Fraction—a Concise Review
133 Obesity is associated with decreased myocardial contraction fraction despite preserved ejection fraction
Gender-related differences in heart failure with preserved ejection fraction
Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
Endostatin a Potential Biomarker for Heart Failure with Preserved Ejection Fraction